668P First-in-human Phase I Dose Escalation Study of ALG.APV-527, a 5T4 Tumor Antigen-Conditional 4-1BB Bispecific Antibody, in Patients with Advanced Solid Tumors, Demonstrates Positive Safety, Signals of Biological Activity and Patients with Lasting Stable Disease

T. Marron, S. Rosen, D. Orr,J. Powderly, N. Khaskhely, L. Bonham, M. Nelson, C. Taromino, D. Taylor,J. Kumer, P. Ellmark, S. Fritzell, S.V. Ambarkhane, D. Huebner,A. Alahmadi

Annals of Oncology（2024）

引用 0|浏览2